SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

-  Study Reaches Pre-Specified Threshold of 60 Events (Deaths) Initiating the Interim Analysis –

-  REGAL Independent Data Monitoring Committee to Perform Interim Analysis in January 2025 -

Read more at globenewswire.com